NL
XLO icon

NWAM LLC’s Xilio Therapeutics XLO Stock Holding History

NWAM LLC’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-714
Closed -$26.2K – 556
2023
Q2 		$26.2K Hold
714
– – ﹤0.01% 531
2023
Q1 		$31.7K Hold
714
– – ﹤0.01% 475
2022
Q4 		$26.9K Hold
714
– – ﹤0.01% 508
2022
Q3 		$29K Buy
+714
New +$27.7K ﹤0.01% 478

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
TOCUITCONY
Trustees of Columbia University in the City of New York New York $891M AUM 17.3% 1-Year Est. Return

NWAM LLC's XLO Position: Q3 2023 in Review

NWAM LLC sold out of Xilio Therapeutics (XLO) in Q3 2023, closing a stake of 714 shares — an estimated $26.2K sold.

NWAM LLC first reported a position in XLO in Q3 2022 and held it in 4 quarters. The position peaked at $31.7K in Q1 2023. 30 funds tracked by Wall St. Rank hold XLO as of Q3 2023.

  • NWAM LLC reported no remaining Xilio Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NWAM LLC sold 714 Xilio Therapeutics shares in Q3 2023, an estimated $26.2K.
  • NWAM LLC first reported a position in Xilio Therapeutics in Q3 2022 and held it in 4 quarters.
  • NWAM LLC's Xilio Therapeutics position peaked at $31.7K in Q1 2023.
  • 30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2023.

Based on NWAM LLC's 13F filing for Q3 2023, filed 1 Nov 2023.